<?xml version="1.0" encoding="UTF-8"?>
<p>A total of 380 patients participated in the survey, the majority being females (63.2%). Around 132 (34.7%) had rheumatoid arthritis, 68 (17.9%) had connective tissue disease, and 40 (10.5%) had spondyloarthropathy requiring treatment with either disease-modifying antirheumatic drugs (DMARDs) or immunosuppressant therapy. The medication being used by the majority (50.5%) was DMARDs (methotrexate and sulfasalazine alone or in combination). Immunosuppressant therapy (cyclophosphamide, mycophenolate mofetil, or azathioprine) and biological agents (adalimumab, etanercept, or tofacitinib) were being used by 7.4% each. Other demographic parameters are mentioned in 
 <xref rid="t0001" ref-type="table">Table 1</xref>. 
</p>
